Pharmaceutical composition for treating tumor
US12036204B2 · kind B2 · utility
0Cited by
24References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 28, 2021 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Dec 28, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.